CA2995642A1 - Compositions and methods for treating ewing family tumors - Google Patents

Compositions and methods for treating ewing family tumors Download PDF

Info

Publication number
CA2995642A1
CA2995642A1 CA2995642A CA2995642A CA2995642A1 CA 2995642 A1 CA2995642 A1 CA 2995642A1 CA 2995642 A CA2995642 A CA 2995642A CA 2995642 A CA2995642 A CA 2995642A CA 2995642 A1 CA2995642 A1 CA 2995642A1
Authority
CA
Canada
Prior art keywords
tyrosine kinase
kinase inhibitor
biguanide compound
imatinib
metformin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2995642A
Other languages
English (en)
French (fr)
Inventor
Hong Zhao
Stephen T.C. Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Methodist Hospital
Original Assignee
The Methodist Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Methodist Hospital filed Critical The Methodist Hospital
Publication of CA2995642A1 publication Critical patent/CA2995642A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2995642A 2015-08-24 2016-08-22 Compositions and methods for treating ewing family tumors Abandoned CA2995642A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562209197P 2015-08-24 2015-08-24
US62/209,197 2015-08-24
US201562209645P 2015-08-25 2015-08-25
US62/209,645 2015-08-25
PCT/US2016/047984 WO2017035057A1 (en) 2015-08-24 2016-08-22 Compositions and methods for treating ewing family tumors

Publications (1)

Publication Number Publication Date
CA2995642A1 true CA2995642A1 (en) 2017-03-02

Family

ID=58101236

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2995642A Abandoned CA2995642A1 (en) 2015-08-24 2016-08-22 Compositions and methods for treating ewing family tumors

Country Status (7)

Country Link
US (1) US10765675B2 (enExample)
EP (1) EP3340978A4 (enExample)
JP (1) JP2018525413A (enExample)
CN (1) CN106714795A (enExample)
CA (1) CA2995642A1 (enExample)
TW (1) TW201717926A (enExample)
WO (1) WO2017035057A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108034726B (zh) * 2018-01-18 2021-07-30 四川大学华西医院 检测mlh1表达水平的试剂在制备肿瘤靶向药敏感性检测试剂盒中的用途
WO2022093789A1 (en) * 2020-10-27 2022-05-05 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of apex, alone and in combination with other cancer drugs to inhibit growth of cancer cells
WO2025097033A1 (en) * 2023-11-01 2025-05-08 City Of Hope Metformin combination therapy for use in cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641940A4 (en) 2003-07-01 2009-09-02 Mor Research Applic Ltd DETERMINING PROGNOSIS IN PATIENTS WITH EWING SARCOMA BY GENETIC PROFILES
WO2008089034A2 (en) * 2007-01-11 2008-07-24 Kemia, Inc. Cytokine inhibitors
WO2011050210A1 (en) * 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011072174A1 (en) * 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
AU2014293013A1 (en) * 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene

Also Published As

Publication number Publication date
EP3340978A4 (en) 2019-04-10
EP3340978A1 (en) 2018-07-04
WO2017035057A1 (en) 2017-03-02
JP2018525413A (ja) 2018-09-06
TW201717926A (zh) 2017-06-01
US10765675B2 (en) 2020-09-08
US20180243299A1 (en) 2018-08-30
CN106714795A (zh) 2017-05-24

Similar Documents

Publication Publication Date Title
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
Liu et al. A Phase 1 trial of the poly (ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
EP2154971B1 (en) A synergistic pharmaceutical combination for the treatment of cancer
JP2019521971A (ja) がんの処置
CN109152839A (zh) 双极性反式类胡萝卜素连同化疗和放射治疗在治疗癌症中的用途
CA3227308A1 (en) Treating cancers with combinations of spironolactone and acylfulvenes
US10765675B2 (en) Compositions and methods for treating Ewing family tumors
Jang et al. Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models
US9901594B2 (en) Pharmaceutical composition and uses thereof
KR20040062546A (ko) 병용 요법에 이용되는 수라민의 약제감작화 용량을결정하는 방법 및 조성물
US20210379095A1 (en) Methods and Combination Therapy to Treat Biliary Tract Cancer
WO2006045541A1 (en) Treatment and prevention of multi-drug resistance
US10238679B2 (en) Antitumor activity of multi-kinase inhibitors in colorectal cancer
JP6581308B2 (ja) 癌治療剤
CA3135916A1 (en) Combined use of a-nor-5a androstane compound drug and anticancer drug
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
HK40046230A (en) IRE1α INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT
HK40038981A (en) Methods and combination therapy to treat biliary tract cancer
Lubieniecka et al. 367 POSTER Histone deacetylase inhibitors reactivate MEIS2 in synovial sarcoma
HK1188572B (en) Combination therapy with an antitumor alkaloid
HK1202421B (en) Combination therapy with an antitumor antibiotic

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220301